Dicerna Expects Industry Deal in ‘09, Takes Aim at Undruggable Targets | GenomeWeb

Leveraging a strategy of pursuing targets undruggable by technologies other than RNAi, Dicerna Pharmaceuticals has set its sights on inking at least one industry alliance in 2009, a company official told RNAi News this week.

While “nothing is done until it’s done in this business … [discussions] are progressing very well in a very serious manner,” and Dicerna plans to have consummated its first industry partnership before the end of the year, CEO Jim Jenson said. He added that the company intends to primarily strike deals on a target-by-target basis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.